Jennison Associates
SGMO

Jennison Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Jennison Associates’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-515,643
Closed -$4.67M – 663
2019
Q3 		$4.67M Buy
+515,643
New +$5.78M ﹤0.01% 462
2015
Q3 		– Sell
-1,731,499
Closed -$19.2M – 762
2015
Q2 		$19.2M Buy
1,731,499
+13,577
+0.8% +$175K 0.02% 462
2015
Q1 		$26.9M Buy
1,717,922
+4,273
+0.2% +$66.1K 0.02% 408
2014
Q4 		$26.1M Sell
1,713,649
-54,743
-3% -$665K 0.02% 413
2014
Q3 		$19.1M Sell
1,768,392
-89,426
-5% -$1.17M 0.02% 439
2014
Q2 		$28.4M Sell
1,857,818
-158,395
-8% -$2.28M 0.03% 403
2014
Q1 		$36.5M Buy
2,016,213
+108,670
+6% +$2.09M 0.03% 376
2013
Q4 		$26.5M Buy
1,907,543
+421,045
+28% +$4.85M 0.03% 416
2013
Q3 		$15.6M Buy
+1,486,498
New +$14.8M 0.02% 455

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates's SGMO Position: Q4 2019 in Review

Jennison Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2019, closing a stake of 515,643 shares — an estimated $4.67M sold.

Jennison Associates first reported a position in SGMO in Q3 2013 and held it in 9 quarters. The position peaked at $36.5M in Q1 2014. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2019.

  • Jennison Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2019 after selling out during the quarter.
  • Jennison Associates sold 515,643 SANGAMO THERAPEUTICS INC shares in Q4 2019, an estimated $4.67M.
  • Jennison Associates first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 9 quarters.
  • Jennison Associates's SANGAMO THERAPEUTICS INC position peaked at $36.5M in Q1 2014.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2019.

Based on Jennison Associates's 13F filing for Q4 2019, filed 7 Feb 2020.